Maravai LifeSciences Holdings, Inc. MRVI
Set alert
7.19 USD -0.62 -7.94%
At close · Nov 2
7.19 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
7.16 Day range 7.99
2.55 52-week range 9.42
- YTD
- +121.23%
- 1 year
- +128.98%
- Open
- 7.81
- Prev close
- 7.81
- Mkt cap
- 2.66B
- Vol
- 2.29M
- Avg vol
- 3.18M
- EPS
- -0.53
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 7.16
- High
- 7.99
- Forward P/E
- -71.43
- Beta
- 0.63
- Short ratio
- 4.94
- Inst. own
- 99.22%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 7.50
- 200-d avg
- 5.24
- 1y target
- 8.50
Analyst view
Consensus: buy
Buy
Price target (mean) 8.50 +18.2% upside
Now 7.19
- Target (low)
- 7.00
- Target (mean)
- 8.50
- Target (high)
- 12.00
Ratings (0m) 9 5 buy · 4 hold · 0 sell
- Strong buy0
- Buy5
- Hold4
- Sell0
- Strong sell0
Recommendation trend
- This month 9
- 1 month ago 8
- 2 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.05584 | -0.07725 – -0.04 | -0.08 | +30.2% | 43.56M | +4.6% | 9 |
| Next quarter | -0.04406 | -0.06603 – -0.03 | -0.04 | -10.2% | 50.92M | +2.1% | 8 |
| Current year | -0.10739 | -0.15032 – -0.08 | -0.29 | +63.0% | 211.77M | +14.0% | 9 |
| Next year | -0.10066 | -0.20 – -0.02 | -0.10739 | +6.3% | 224.89M | +6.2% | 9 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 9, 2026 | UBS | Maintained | Neutral | Neutral |
| Aug 7, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| May 8, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Dec 15, 2025 | Wells Fargo | Maintained | Overweight | Overweight |
| Aug 12, 2025 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 12, 2025 | Craig-Hallum | Maintained | Buy | Buy |
| May 13, 2025 | Craig-Hallum | Maintained | Buy | Buy |
| May 13, 2025 | Baird | Maintained | Neutral | Neutral |
| Mar 25, 2025 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Mar 21, 2025 | UBS | Maintained | Neutral | Neutral |
| Mar 3, 2025 | B of A Securities | Maintained | Buy | Buy |
| Feb 26, 2025 | Baird | Downgrade | Outperform | Neutral |
| Dec 5, 2024 | Goldman Sachs | Downgrade | Neutral | Sell |
| Nov 14, 2024 | Wolfe Research | Initiated | — | Peer Perform |
| Nov 8, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| Nov 8, 2024 | William Blair | Downgrade | Outperform | Market Perform |
| Nov 8, 2024 | Baird | Maintained | Outperform | Outperform |
| Oct 8, 2024 | Goldman Sachs | Maintained | Neutral | Neutral |
| Aug 27, 2024 | Wells Fargo | Initiated | — | Overweight |
| Aug 16, 2024 | RBC Capital | Reiterated | Outperform | Outperform |
| Aug 13, 2024 | Morgan Stanley | Downgrade | Overweight | Equal-Weight |
| Aug 8, 2024 | Goldman Sachs | Maintained | Neutral | Neutral |
| Aug 8, 2024 | UBS | Maintained | Neutral | Neutral |
| Jul 9, 2024 | Goldman Sachs | Maintained | Neutral | Neutral |
| May 9, 2024 | Baird | Maintained | Outperform | Outperform |
| Apr 10, 2024 | Craig-Hallum | Initiated | — | Buy |
| Feb 23, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| Feb 23, 2024 | Stifel | Maintained | Buy | Buy |
| Dec 12, 2023 | B of A Securities | Upgrade | Neutral | Buy |
| Nov 9, 2023 | Goldman Sachs | Maintained | Neutral | Neutral |